Aarti Pharmalabs Ltd reports Q2 FY27 revenue of ₹610.45 crore, up 45.9% YoY, and net profit of ₹71.47 crore.
- Estimated EBITDA operating margin was 22.1%, versus 25.4% in Q1 FY27 and 15.4% in Q2 FY26.
- Results include a ₹2.04 crore exceptional provision for a stamp-duty order; a further ₹57.46 crore is disclosed as contingent liability, and the company has challenged the order.
- CFO Piyush Lakhani resigns effective October 30; Vibha Thakkar takes over from October 31, 2026.